Skjøth-Rasmussen Jane, Azam Aleena, Larsen Carl Christian, Scheie David, Juhl Karina, Kjaer Andreas
Department of Neurosurgery, Neuroscience Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Acta Neurochir (Wien). 2022 Jan;164(1):267-271. doi: 10.1007/s00701-021-05051-3. Epub 2021 Nov 8.
Meningiomas are benign lesion although anot insignificant number experiences recurrences despite Simpson grade 1 removal. FG001 is a compound with a fluorophore (ICG) that binds to a urokinase-type plasminogen activator receptor (uPAR) and is currently investigated at our institution in a first-in-human trial. The patient presented with a plausible malignant glioma but proved to be a grade 1 meningioma. FG001 could delineated the tumor not only on the surface but supplementary in the cavity to remove safely the dural attachment. We present FG001 as a new promising tool for improved surgical radicality beyond the intended indication, provided that a prospective validation in a consecutive meningioma cohort demonstrates similar results.
脑膜瘤是良性病变，尽管相当数量的病例在辛普森1级切除术后仍会复发。FG001是一种含有与尿激酶型纤溶酶原激活物受体（uPAR）结合的荧光团（吲哚菁绿，ICG）的化合物，目前正在我们机构进行首次人体试验。该患者最初表现为疑似恶性胶质瘤，但最终被证实为1级脑膜瘤。FG001不仅可以在肿瘤表面显影，还能在瘤腔内显影，从而安全地切除硬脑膜附着处。如果在连续的脑膜瘤队列中进行的前瞻性验证显示出相似的结果，我们认为FG001是一种有望提高手术根治性的新工具，其作用超出了预期适应症。
